Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Nimorazole - AFYX Therapeutics

Next Previous
Drug Profile

Nimorazole - AFYX Therapeutics

Alternative Names: AFYX-001

Latest Information Update: 10 Jun 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator AFYX Therapeutics
  • Class Antibacterials; Antineoplastics; Antiprotozoals; Ethylenediamines; Morpholines; Nitrites; Nitroimidazoles; Radiation-sensitising agents; Radiosensitisers; Small molecules
  • Mechanism of Action DNA repair inhibitors; DNA synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preregistration Squamous cell cancer

Most Recent Events

  • 10 Jun 2026 Preregistration for Squamous cell cancer (Late-stage disease) (PO), prior to June 2026 (AFYX Therapeutics pipeline, June 2026)
  • 22 Apr 2026 Chemical structure information added.
  • 21 Apr 2026 AFYX Therapeutics announces intention to submit NDA for Head and neck cancer in third quarter of 2026

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top